Dupixent (Dupilumab)
The Dupixent (Dupilumab) Products Liability Litigation was centralized before Judge Zahid N. Quraishi in the District of New Jersey in June 2026, consolidating federal claims against the manufacturers of the biologic drug dupilumab, marketed for eczema, asthma, and several other inflammatory conditions. With only 36 total actions filed and 35 pending as of the JPML's most recent report, this is among the newest dockets in the federal MDL system — centralization at this volume typically reflects the JPML's judgment that even a modest number of overlapping claims justifies coordinated pretrial handling to avoid duplicative discovery, rather than any conclusion about the claims' merits.
At this earliest phase, the structural questions that will define the litigation's duration and resolution path are still open: no case-management order, leadership structure, or master complaint framework has had time to mature, and no general-causation record yet exists in this proceeding for the alleged injury pattern connected to dupilumab use. Duration risk here is driven almost entirely by how quickly the court can establish a pretrial schedule, how many additional cases are transferred in or newly filed as awareness of the litigation grows, and — once that structure is in place — how a bellwether selection process is designed.
This is precisely the stage in an MDL's life cycle where a regulated outcomes intelligence view is most valuable: understanding how comparable young dockets have typically structured their early pretrial phases, without projecting a specific causation finding or claim value onto this one. Criterica Intelligence's platform tracks this structural trajectory across every active MDL, from a docket's first weeks through bellwether and resolution, giving a consistent structural read regardless of a litigation's age.
The JPML centralizes cases when it finds that common factual questions justify coordinated pretrial handling, even at modest case volumes, to avoid duplicative discovery and inconsistent rulings across districts.
Courts generally establish a leadership structure for plaintiffs' counsel, set an initial case-management schedule, and begin building toward a master complaint before any bellwether selection process starts.
At this stage, duration depends on how quickly the court establishes pretrial structure, how many additional cases are filed or transferred in, and how a future bellwether program is designed once discovery matures.
No. The platform provides a structural read of how the docket is organized and how comparable litigation has typically progressed, not a prediction of a specific causation finding or case outcome.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.